Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives

Posted: December 10, 2021 at 1:55 am

DENVER, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has entered into an agreement with an investor to complete a non-brokered private placement (the “Financing” ) of a convertible secured subordinated debenture (the “Debenture”) in the principal amount of C$5.5 million. The Financing is expected to close on December 10, 2021.

View original post here:
Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives

Related Posts